ReviewPharmaceutical research2017
Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.
Review in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 58 citations in OpenAlex.
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Review
- Transforming dementia research into practice: a multiple case study of academic research utilization strategies in Dutch Alzheimer Centres.Health research policy and systems · 2025Article
- Stem Cells as a Novel Source for Regenerative Medicinal Applications in Alzheimer's Disease: An Update.Current molecular medicine · 2025Review
- Establishment of Advanced Regulatory Innovation for Clinical Trials Transformation (ARICTT): a multi-stakeholder public-private partnership-based organization to accelerate the transformation of clinical trials.Translational and clinical pharmacology · 2024Article
- From Innovator Result-driven to Multi-actor Impact-oriented Public-Private Partnerships: Integrating the Patient Perspective.Handbook of experimental pharmacology · 2024Review
- Article
- Talking Ethics Early in Health Data Public Private Partnerships.Journal of business ethics : JBE · 2024Article
- Adoption and use of immunotherapy in breast cancer management in Africa: barriers and prospect - a narrative review.Annals of medicine and surgery (2012) · 2023Review
- Public-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases.PLoS neglected tropical diseases · 2023Article
- Use of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation.Neuroscience and biobehavioral reviews · 2023Review
- Participating in innovative medicines initiative funded neurodegenerative disorder projects-An impact analysis conducted as part of the NEURONET project.Frontiers in neurology · 2023Article
- Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond.Pharmaceutical medicine · 2022Review
- Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2022Article
- The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks.Frontiers in neurology · 2022Article
- Lessons learnt from implementing the Good Governance for Medicines Programme in Zimbabwe.BMJ global health · 2022Article
- Governing antimicrobial resistance: a narrative review of global governance mechanisms.Journal of public health policy · 2020Review
- Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.Blood advances · 2019Article
- Editorial: Public-Private Partnerships as Drivers of Innovation in Healthcare.Frontiers in medicine · 2019Article
- Innovative Approaches to Increase Access to Medicines in Developing Countries.Frontiers in medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.